HUP0202625A2 - Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries - Google Patents

Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries

Info

Publication number
HUP0202625A2
HUP0202625A2 HU0202625A HUP0202625A HUP0202625A2 HU P0202625 A2 HUP0202625 A2 HU P0202625A2 HU 0202625 A HU0202625 A HU 0202625A HU P0202625 A HUP0202625 A HU P0202625A HU P0202625 A2 HUP0202625 A2 HU P0202625A2
Authority
HU
Hungary
Prior art keywords
binding
dye conjugates
angiogenesis
intraoperatively
order
Prior art date
Application number
HU0202625A
Other languages
English (en)
Inventor
Dinkelborg
Licha
Schirner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7924318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0202625(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of HUP0202625A2 publication Critical patent/HUP0202625A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány olyan antitest-színezék-konjugátumokra vonatkozik, amelyekalkalmasak újonnan képződött véredények struktúráihoz kötődni, és ezekalkalmazására patológiás angingenezis operáció alatti (intraoperatív)megjelenítéséhez. A találmány szerinti antitest-színezék-konjugátumokés ezeket tartalmazó gyógyszerkészítmények felhasználhatók tumorokkörvonalainak operáció alatti meghatározására és ezáltal a tumorokpontosabb eltávolítására. Ó
HU0202625A 1999-09-24 2000-08-19 Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries HUP0202625A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947559A DE19947559A1 (de) 1999-09-24 1999-09-24 Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
PCT/EP2000/008121 WO2001023005A1 (de) 1999-09-24 2000-08-19 Antikörper-farbstoffkonjugate gegen zielstrukturen der angiogenese zur intraoperativen tumorranddarstellung

Publications (1)

Publication Number Publication Date
HUP0202625A2 true HUP0202625A2 (en) 2002-12-28

Family

ID=7924318

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202625A HUP0202625A2 (en) 1999-09-24 2000-08-19 Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries

Country Status (23)

Country Link
EP (2) EP1532988A3 (hu)
JP (1) JP2003510294A (hu)
KR (2) KR20070087232A (hu)
CN (1) CN1269530C (hu)
AU (1) AU779026B2 (hu)
BG (1) BG65682B1 (hu)
BR (1) BR0014192A (hu)
CA (1) CA2385593A1 (hu)
CZ (1) CZ2002991A3 (hu)
DE (1) DE19947559A1 (hu)
EE (1) EE05176B1 (hu)
HK (1) HK1050491A1 (hu)
HU (1) HUP0202625A2 (hu)
IL (2) IL148405A0 (hu)
MX (1) MXPA02002639A (hu)
NO (1) NO20021441L (hu)
NZ (1) NZ517944A (hu)
RO (1) RO121598B1 (hu)
RU (1) RU2002109237A (hu)
SK (1) SK3972002A3 (hu)
WO (1) WO2001023005A1 (hu)
YU (1) YU20702A (hu)
ZA (1) ZA200203225B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
NO20034351D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av endometrose
EP1816475A1 (en) * 2004-07-22 2007-08-08 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
US20120041305A1 (en) * 2009-04-21 2012-02-16 The University Of Utah Research Foundation Light-emitting dye for intraoperative imaging or sentinel lymph node biopsy
EP3493855A4 (en) * 2016-08-02 2020-04-01 ISI Life Sciences, Inc. METHOD FOR DETECTION OF CANCER CELLS.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
CN1162184C (zh) * 1994-07-11 2004-08-18 德克萨斯州立大学董事会 用于脉管系统特异性凝血的组合物及其应用
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

Also Published As

Publication number Publication date
KR20070087232A (ko) 2007-08-27
IL148405A0 (en) 2002-09-12
NO20021441L (no) 2002-05-15
DE19947559A1 (de) 2001-04-19
AU6702600A (en) 2001-04-30
HK1050491A1 (en) 2003-06-27
RU2002109237A (ru) 2003-11-27
CN1376074A (zh) 2002-10-23
KR20020039349A (ko) 2002-05-25
EP1532988A3 (de) 2008-09-17
SK3972002A3 (en) 2002-09-10
WO2001023005A1 (de) 2001-04-05
EE05176B1 (et) 2009-06-15
NZ517944A (en) 2004-06-25
BR0014192A (pt) 2002-05-21
BG65682B1 (bg) 2009-06-30
EP1214099A1 (de) 2002-06-19
BG106528A (bg) 2002-12-29
MXPA02002639A (es) 2002-07-30
EP1532988A2 (de) 2005-05-25
JP2003510294A (ja) 2003-03-18
YU20702A (sh) 2005-06-10
ZA200203225B (en) 2003-07-23
NO20021441D0 (no) 2002-03-22
CN1269530C (zh) 2006-08-16
CA2385593A1 (en) 2001-04-05
KR100832937B1 (ko) 2008-05-27
CZ2002991A3 (cs) 2002-06-12
RO121598B1 (ro) 2007-12-28
IL148405A (en) 2009-06-15
PL354027A1 (en) 2003-12-15
AU779026B2 (en) 2005-01-06
EE200200152A (et) 2003-04-15

Similar Documents

Publication Publication Date Title
DK11391A (da) Alkoxy-4(1h)-pyridonderivater og farmakologisk acceptable salte deraf, deres fremstilling og anvendelse
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
DE50014699D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
HUP0102661A2 (hu) BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk
WO2002099048A3 (en) LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
WO2002099060A3 (en) Dgks as modifiers of the p53 pathway and methods of use
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
NO853700L (no) Blodkoaguleringshemmende proteiner og fremgangsm¨te for fr emstilling derav.
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
DK1017675T3 (da) Stærkt lipofile camptothecinderivater
HUP0202625A2 (en) Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries
HUP9900154A2 (hu) Trovafloxacin-mezilát tabletta
HUP0100170A1 (hu) N-benzil-3-indenil-acetamid-származékok és alkalmazásuk neoplázia kezelésére alkalmas gyógyszerkészítmények előállítására
NZ524936A (en) Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor
PT1233787E (pt) Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
DE69926251D1 (de) Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
YU63702A (sh) Novo antitelo sa specifičnošću za rak debelog creva
WO2002059609A3 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2004094451A3 (de) 8beta-vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene
WO2002021134A3 (en) Methods of diagnosing breast cancer and screening for modulators

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees